Molecular Partners expands and advances robust pipeline of DARPin® therapies in oncology and ophthalmology

By | Uncategorized | No Comments

Molecular Partners holds its R&D update in New York, entitled “The DARPin® Difference – Offering Patients a New Dimension of Protein Therapeutics”, which features a series of presentations highlighting the scientific rationale and the potential clinical impact of the DARPin® approach, as well as the company’s continued forward integration and evolution towards becoming a fully integrated biopharmaceutical company.

Read More